IDN 7314

Drug Profile

IDN 7314

Alternative Names: IDN-7314

Latest Information Update: 23 Apr 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Conatus Pharmaceuticals
  • Class Hepatoprotectants
  • Mechanism of Action Apoptosis inhibitors; Caspase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Primary sclerosing cholangitis
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Primary sclerosing cholangitis

Most Recent Events

  • 18 Apr 2018 Pharmacodynamics data from a preclinical trial in Primary sclerosing cholangitis released by Conatus Pharmaceuticals
  • 09 Apr 2018 Pharmacodynamics data from a preclinical trial in primary sclerosing cholangitis released by Conatus Pharmaceuticals
  • 18 Oct 2017 IDN 7314 receives Orphan Drug status for Primary sclerosing cholangitis in European Union
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top